




CDDF MULTI-STAKEHOLDER WORKSHOP

# IMPACT OF THE MICROBIOME ON CANCER GROWTH AND THERAPY

Munich, Germany  
15 - 16 February 2019

**PROGRAMME**




# PROGRAMME

## Day 1 – Friday 15 February 2019

- 14:00 **Welcome**  
(V. Nuessler, Munich Tumour Centre; H. Zwierzina, CDDF)

### SESSION 1


*Co-chairs: Giorgio Trinchieri, Heinz Zwierzina*

- 14:15 **Keynote lecture: Microbiome and immune system in cancer**  
Laurence Zitvogel (Gustave Roussy, Paris, France)
- 14:50 **Microbiota-mediated metabolic health**  
Soraya Taleb (Paris-Centre de Recherche Cardiovasculaire, Paris, France)
- 15:10 **Shaping of adaptive immunity by the microbiota**  
Hyun-Dong Chang (Deutsches Rheuma-Forschungszentrum Berlin, Germany)
- 15:30 **Effects of non-antibiotics on the microbiome**  
Georg Zeller (EMBL Heidelberg, Germany)
- 15:50  COFFEE BREAK

### SESSION 2

*Co-chairs: Laure Bindels, Volkmar Nüssler*


- 16:20 **Potential of fecal microbiota for early-stage detection of colorectal cancer**  
Georg Zeller (EMBL Heidelberg, Germany)
- 16:40 **Crosstalk of the microbiome and epithelial cells**  
Dirk Haller (Technische Universität München, Germany)
- 17:00 **Regulation of life span by the gut microbiome**  
Dario Riccardo Valenzano (Max Planck Institute for Biology of Ageing, Germany)
- 17:20 **Applying systems-biology to study the mechanistic interactions of the gut microbiota**  
Naama Geva-Zatorsky (Technion, Israel)

- 17:40 **Gut microbiota-derived propionate reduces cancer cell proliferation in the liver**  
Laure Bindels (Université Catholique de Louvain, Belgium)
- 18:00 **Microbiome restoration therapy in acute myeloid leukemia**  
Ronald Carter (Maat-Pharma, France)
- 18:20 End of day 1
- 19:30  **Networking dinner**  
Zum Franziskaner (Residenzstraße 9, 80333 Munich)

## Day 2 – Saturday 16 February 2019

### SESSION 3

*Co-chairs: Laurence Zitvogel, Maria Vehreschild*



- 09:30 **Keynote lecture: Microbiome and immunotherapy in cancer**  
Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
- 10:05 **Interplay of innate lymphoid cells and the microbiota**  
Andreas Diefenbach (Charité – Universitätsmedizin Berlin, Germany)
- 10:25 **The role of microbiota in GvHD and complications of allogeneic SCT**  
Ernst Holler (Universitätsklinikum Regensburg, Germany)
- 10:45 **The intra-tumoral bacterial flora – potential implications**  
Mark Tangney (University College Cork, Ireland)
- 11:05  COFFEE BREAK

## SESSION 4

*Co-chairs: Andreas Diefenbach, Dirk Haller*

- 11:35 **Monoclonal microbials and cancer therapy**  
Mark Bodmer (Evelo Biosciences, USA)
- 11:55 **Establishing fecal microbiota transfer in Germany – a steep and stony path**  
Maria Vehreschild (University Hospital Cologne, Germany)
- 12:15 **Challenges in regulating microbiota**  
Anja Düchting (BfArM, Germany)
- 12:35 **Enhancement of anti-tumor immunity via targeted alteration of the microbiome**  
Bernat Olle (Vedanta Biosciences, USA)

## CLOSING REMARKS

- 12:55  **Concluding remarks and discussion**  
(L. Zitvogel, G. Trinchieri, A. Diefenbach, D. Haller, V. Nüssler, H. Zwierzina)
- 13:15  **END OF THE MEETING / LUNCH**

## Event Outline

The workshop on Impact of the Microbiome on Cancer Growth and Therapy is organized by the Cancer Drug Development Forum (CDDF) in cooperation with the Munich Tumour Centre (TzM), with the aim of enhancing the understanding of the human microbiome and its critical role in cancer growth and treatment. The workshop provides comprehensive insights into the human microbiome and its application to cancer research as well as valuable opportunities to establish network in the emerging microbiome field.

The first edition of the CDDF workshop on Impact of the Microbiome on Cancer Growth and Therapy will be held on 15 - 16 June 2018, in Munich, Germany and will offer small group lectures and interactive discussions to effectively exchange expertise and broaden perspectives. The lectures will focus on the links between the human microbiome and cancer with a special attention to inflammation and immune system.

During the workshop, participants will enhance their knowledge of the current and future development in the microbiome research and its clinical relevance. Most importantly, delegates will network with various players and experts in the emerging microbiome sector.

## Programme Committee

- Matthew Albert (Roche/Genentech, USA)
- Phillip Dennis (AstraZeneca, USA)
- Andreas Diefenbach (Charite – Universitaetsmedizin Berlin, Germany)
- Volkmar Nuessler (CDDF/Tumour Centre, Munich, Germany)
- Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
- Laurence Zitvogel (Gustave Roussy, France)
- Heinz Zwierzina (CDDF/Innsbruck University Hospital, Austria)

## Target Audience

The target audience is a multi-disciplinary community of researchers, medical oncologists, nutritionists and other healthcare professionals, representatives from pharmaceutical, nutrition and biomedical industries, patient advocates, and students who have a keen interest in microbiome research.

